Analysts think MREO stock price could increase by 89%
Dec 27, 2024, 12:26 PM
-22.81%
What does MREO do
Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
9 analysts think MREO stock price will increase by 89.39%. The current median analyst target is $7.14 compared to a current stock price of $3.77. The lowest analysts target is $5.76 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.